Product logins

Find logins to all Clarivate products below.


: Drugs to Watch

Here you will find relevant articles and insight into all Clarivate related products and news.

Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022 Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Blog June 23, 2022
Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022
Clinical research Clinical trials Drugs to Watch
Expected blockbusters: A year in progress Expected blockbusters: A year in progress
Blog November 18, 2019
Expected blockbusters: A year in progress
Drugs to Watch
Potential blockbusters make a splash on market entry Potential blockbusters make a splash on market entry
Blog June 13, 2019
Potential blockbusters make a splash on market entry
blockbuster Cortellis Cortellis Analytics
Blog March 20, 2019
Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019
autoimmunity Blockbusters Breakthrough Therapy
Blog October 31, 2018
Indivior’s Sublocade contributing to transformation of opioid dependence market
Blockbuster drugs buprenorphine Cortellis
Blog October 18, 2018
Roche’s Hemlibra: Market expansion approved, but safety an initial concern?
Drugs to Watch
Blog October 3, 2018
Erleada gains first-mover advantage in CRPC
apalutamide Blockbuster drugs Cortellis
Blog September 19, 2018
Shire’s Takhzyro expected to dominate in hereditary angioedema
Drugs to Watch Portfolio strategy Rare diseases

Drugs to Watch

Blog July 13, 2017
Checkpoint inhibitors: a cutting edge in oncology